December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

458.21 -4.69 (-1.01%)
Streaming Delayed Price Updated: 2:42 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
69 70 Next >
News headline image
3 Monster Stocks to Buy Without Any Hesitation ↗
These are easy choices for investors seeking market-beating long-term gains. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
News headline image
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
News headline image
1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗
The stock has been in the news lately. 
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on VRTX Options ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Vertex Pharmaceuticals? ↗
 
Via Benzinga
News headline image
$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
After This Landmark Win, Is CRISPR Therapeutics a Buy? ↗
CRISPR Therapeutics stock already has advanced in the double digits this year. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy With Your End-of-the-Year Bonus ↗
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
News headline image
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
News headline image
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
News headline image
Should you consider NASDAQ:VRTX for quality investing? ↗
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
News headline image
Is Vertex Pharmaceuticals Sitting on a Gold Mine? ↗
Vertex shares have climbed about 40% this year. 
Via The Motley Fool
News headline image
Why Vertex Stock Is Soaring Today ↗
The drugmaker's non-opioid painkiller is showing promise in a select set of patients. 
Via The Motley Fool
News headline image
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief ↗
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
News headline image
Better Growth Stock: Archer Aviation or Prime Medicine? ↗
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
News headline image
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich ↗
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? ↗
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
News headline image
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip ↗
This biotech could have more winners on the way. 
Via The Motley Fool
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review ↗
The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030 ↗
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy. 
Via InvestorPlace
Topics ETFs
News headline image
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 ↗
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
News headline image
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700... 
Via Benzinga
News headline image
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday? ↗
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
News headline image
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial ↗
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage  
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.